These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

135 related articles for article (PubMed ID: 36924788)

  • 1. Can a single dose of Modified Vaccinia Ankara-Bavarian Nordic vaccine protect against mpox?
    Ogoina D; Strub-Wourgaft N
    Lancet Infect Dis; 2023 Jul; 23(7):768-769. PubMed ID: 36924788
    [No Abstract]   [Full Text] [Related]  

  • 2. Modified vaccinia Ankara-Bavarian Nordic vaccine against mpox in children.
    Turtle L; Subramaniam K
    Lancet Infect Dis; 2023 Sep; 23(9):989-990. PubMed ID: 37336223
    [No Abstract]   [Full Text] [Related]  

  • 3. Short-term Adverse Events Following Immunization With Modified Vaccinia Ankara-Bavarian Nordic (MVA-BN) Vaccine for Mpox.
    Deng L; Lopez LK; Glover C; Cashman P; Reynolds R; Macartney K; Wood N
    JAMA; 2023 Jun; 329(23):2091-2094. PubMed ID: 37145654
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Early evaluation of the safety, reactogenicity, and immune response after a single dose of modified vaccinia Ankara-Bavaria Nordic vaccine against mpox in children: a national outbreak response.
    Ladhani SN; Dowell AC; Jones S; Hicks B; Rowe C; Begum J; Wailblinger D; Wright J; Owens S; Pickering A; Shilltoe B; McMaster P; Whittaker E; Zuo J; Powell A; Amirthalingam G; Mandal S; Lopez-Bernal J; Ramsay ME; Kissane N; Bell M; Watson H; Ho D; Hallis B; Otter A; Moss P; Cohen J
    Lancet Infect Dis; 2023 Sep; 23(9):1042-1050. PubMed ID: 37336224
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Outcomes of post-exposure vaccination by modified vaccinia Ankara to prevent mpox (formerly monkeypox): a retrospective observational study in Lyon, France, June to August 2022.
    Merad Y; Gaymard A; Cotte L; Perpoint T; Alfaiate D; Godinot M; Becker A; Cannesson O; Batalla AS; Oria-Yassir F; Landré S; Morfin F; Bouscambert M; Valour F; Ader F; Conrad A
    Euro Surveill; 2022 Dec; 27(50):. PubMed ID: 36695469
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effectiveness of Modified Vaccinia Ankara-Bavaria Nordic Vaccination in a Population at High Risk of Mpox: A Spanish Cohort Study.
    Fontán-Vela M; Hernando V; Olmedo C; Coma E; Martínez M; Moreno-Perez D; Lorusso N; Vázquez Torres M; Barbas Del Buey JF; Roig-Sena J; Pastor E; Galmés Truyols A; Artigues Serra F; Sancho Martínez RM; Latasa Zamalloa P; Pérez Martínez O; Vázquez Estepa A; García Rojas AJ; Barreno Estévez AI; Sánchez-Migallón Naranjo A; Pérez Martín JJ; Peces Jiménez P; Morales Romero R; Castilla J; García Cenoz M; Huerta Huerta M; Boone ALD; Macías Ortiz MJ; Álvarez Río V; Rodríguez Recio MJ; Merino Díaz M; Berradre Sáenz B; Villegas-Moreno MT; Limia A; Diaz A; Monge S;
    Clin Infect Dis; 2024 Feb; 78(2):476-483. PubMed ID: 37864849
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Human Monkeypox Virus Infection in the Immediate Period After Receiving Modified Vaccinia Ankara Vaccine.
    Hazra A; Rusie L; Hedberg T; Schneider JA
    JAMA; 2022 Nov; 328(20):2064-2067. PubMed ID: 36178700
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Case study: breakthrough mpox infection in Aotearoa New Zealand and Australia after completed two-dose course of subcutaneous modified vaccinia Ankara (MVA-BN) vaccines.
    Cornelisse VJ; Kearley JJM; Vargas Castillo J; Macharg L; McLaughlin VA; Jack SJ; Swift C
    Sex Health; 2023 Dec; 20(6):585-587. PubMed ID: 37852607
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Current Status of Vaccine Development for Monkeypox Virus.
    Rastogi A; Kumar M
    Adv Exp Med Biol; 2024; 1451():289-300. PubMed ID: 38801585
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Characterizing the acute antibody response of monkeypox and MVA-BN vaccine following an Australian outbreak.
    Asquith W; Hueston L; Dwyer D; Kok J; Ko D; Fennel M; Rockett R; Rai NJ; Li Y; Sriramoju S; Sutor A; O'Sullivan M
    J Med Virol; 2024 Jan; 96(1):e29407. PubMed ID: 38240403
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effectiveness of one dose of MVA-BN smallpox vaccine against mpox in England using the case-coverage method: an observational study.
    Bertran M; Andrews N; Davison C; Dugbazah B; Boateng J; Lunt R; Hardstaff J; Green M; Blomquist P; Turner C; Mohammed H; Cordery R; Mandal S; Campbell C; Ladhani SN; Ramsay M; Amirthalingam G; Bernal JL
    Lancet Infect Dis; 2023 Jul; 23(7):828-835. PubMed ID: 36924787
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Predicting vaccine effectiveness for mpox.
    Berry MT; Khan SR; Schlub TE; Notaras A; Kunasekaran M; Grulich AE; MacIntyre CR; Davenport MP; Khoury DS
    Nat Commun; 2024 May; 15(1):3856. PubMed ID: 38719852
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Mpox vaccination and treatment: a systematic review.
    Eslami A; Alimoghadam S; Khoshravesh S; Shirani M; Alimoghadam R; Alavi Darazam I
    J Chemother; 2024 Apr; 36(2):85-109. PubMed ID: 38069596
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Safety and Efficacy of Post-Eradication Smallpox Vaccine as an Mpox Vaccine: A Systematic Review with Meta-Analysis.
    Malone SM; Mitra AK; Onumah NA; Brown A; Jones LM; Tresvant D; Brown CS; Onyia AU; Iseguede FO
    Int J Environ Res Public Health; 2023 Feb; 20(4):. PubMed ID: 36833653
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Real-world effectiveness of a single dose of mpox vaccine in males.
    Wolff Sagy Y; Zucker R; Hammerman A; Markovits H; Arieh NG; Abu Ahmad W; Battat E; Ramot N; Carmeli G; Mark-Amir A; Wagner-Kolasko G; Duskin-Bitan H; Yaron S; Peretz A; Arbel R; Lavie G; Netzer D
    Nat Med; 2023 Mar; 29(3):748-752. PubMed ID: 36720271
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Adverse Reactions After Intradermal Vaccination With JYNNEOS for Mpox in Korea.
    Lim SY; Jung YM; Kim Y; Kim G; Jeon J; Chin B; Kim MK
    J Korean Med Sci; 2024 Mar; 39(8):e100. PubMed ID: 38442725
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Evaluation of the efficacy of modified vaccinia Ankara (MVA)/IMVAMUNE against aerosolized rabbitpox virus in a rabbit model.
    Garza NL; Hatkin JM; Livingston V; Nichols DK; Chaplin PJ; Volkmann A; Fisher D; Nalca A
    Vaccine; 2009 Sep; 27(40):5496-504. PubMed ID: 19632316
    [TBL] [Abstract][Full Text] [Related]  

  • 18. One- and Two-Dose Vaccinations With Modified Vaccinia Ankara-Bavarian Nordic Induce Durable B-Cell Memory Responses Comparable to Replicating Smallpox Vaccines.
    Ilchmann H; Samy N; Reichhardt D; Schmidt D; Powell JD; Meyer TPH; Silbernagl G; Nichols R; Weidenthaler H; De Moerlooze L; Chen L; Chaplin P
    J Infect Dis; 2023 May; 227(10):1203-1213. PubMed ID: 36408618
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Comparison of the immunogenicity and protective efficacy of ACAM2000, MVA, and vectored subunit vaccines for Mpox in rhesus macaques.
    Jacob-Dolan C; Ty D; Hope D; McMahan K; Liu J; Powers OC; Cotter CA; Sciacca M; Wu C; Borducchi E; Bouffard E; Richter H; Velasco J; Teow E; Boursiquot M; Cook A; Feliciano K; Yalley-Ogunro J; Seaman MS; Pessiant L; Lewis MG; Andersen H; Moss B; Barouch DH
    Sci Transl Med; 2024 Mar; 16(740):eadl4317. PubMed ID: 38536937
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Human Mpox Virus Infection After Receipt of Modified Vaccinia Ankara Vaccine-Reply.
    Hazra A; Schneider JA
    JAMA; 2023 Mar; 329(12):1032. PubMed ID: 36976281
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 7.